BELLADONNA (Belladonna)
BELLADONNA risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Belladonna.
BELLADONNA (brand names: Belladonna) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. FDA approved in the United States. Anticholinergic alkaloid with potential for toxicity and cognitive impairment.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
- Recommended maximum duration: 14 days
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
| United States (FDA) | Rx only | FDA approved |
Risk Profile
Anticholinergic alkaloid with potential for toxicity and cognitive impairment.
Regulatory and Compliance Guidance
When BELLADONNA appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
United States FDA / CDC / State WC
FDA approved for use in the United States.
Need to assess this medication across your caseload?
Run a full risk assessment including BELLADONNA interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.